The Atopic Dermatitis market and the approval of Dupixent

The Atopic Dermatitis market and the approval of Dupixent

Slides in the pack:

1. Dupixent, a new biologic targeting severe Atopic Dermatitis from Sanofi and Regeneron has been approved by the FDA (March 2017)
2. The SOLO 1 and SOLO 2 Trials strongly affirmed Dupixent’s utility in moderate – severe AD
3. Epidemiology and market size for Atopic Dermatitis 
4. Landscape of classical treatments for Atopic Dermatitis
5. Recently launched drugs and pipeline for Atopic Dermatitis
6. The payer negotiation strategies adopted by Sanofi and Regeneron for Dupixent